BioNTech's COVID-19 Vaccine Becomes First Foreign Shot To Be Available In Chinese Market

Vandana Singh
1 min read
15
In this article:

  • German Chancellor Olaf Scholz agreed to allow expatriates in China to use BioNTech SE (NASDAQ: BNTX) made COVID-19 vaccine.

  • BioNTech would be the first non-Chinese coronavirus vaccine in China, as Beijing has insisted on administering domestically produced vaccines.

  • BioNTech partners on COVID vaccines with Pfizer Inc (NYSE: PFE) in regions outside Greater China.

  • Also Read: Pfizer/BioNTech Updated Omicron Adapted COVID-19 Vaccine Shows 4-Fold Higher Neutralizing Activity.

  • In October, Moderna Inc's (NASDAQ: MRNA) CEO Stephane Bancel said the company has talked with the Chinese government about supplying COVID-19 vaccines.

  • But the company refused to hand over to China the core intellectual property related to developing its famed COVID-19 vaccine.

  • A spokesperson for BioNTech told Reuters that vaccines for the Chinese market would be initially imported.

  • While the COVID-19 shots are available in Hong Kong, Macau, and Taiwan, the regulatory review for mainland China has not been concluded.

  • BioNTech has said that decision was up to Chinese regulators and did not give any reason for the delay.

  • No other foreign-made COVID shot has gained access to mainland China's market.

  • Price Action: BNTX shares are up 6.44% at $154.60 on the last check Friday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories